Lilly shuffles roles amid growth in U.S. investment, diabetes and obesity treatments
Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better position the company for growth, particularly for growth in U.S. investment and treatments of cardiometabolic conditions.... Read More